Comparative Pharmacology
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus LIVOSTIN.
EPINASTINE HYDROCHLORIDE vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category A/B
Category C
Antihistamine
Antihistamine